Retinoblastoma — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for retinoblastoma. 15 active patents protecting 1 drugs from 1+ originators. First major cliff: 2035. Daily refresh.

1
Approved drugs
15
Active US patents
49/100
Avg vulnerability
$1.0B
Annual revenue covered

Originators in Retinoblastoma

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Baxter 15 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating retinoblastoma. Each bar = one year. Y-axis scaled to peak year (9 patents).

9
35
6
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cytoxan (Lyophilized)
cyclophosphamide
 Baxter 15 49 $1.0B 2035-06-26

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12329767 Cytoxan (Lyophilized) formulation 55 2036-02-15
12329767 Cytoxan (Lyophilized) formulation 55 2036-02-15
12329767 Cytoxan (Lyophilized) formulation 55 2036-02-15
9662342 Cytoxan (Lyophilized) formulation 50 2035-06-26
10849916 Cytoxan (Lyophilized) formulation 50 2035-07-13
10849916 Cytoxan (Lyophilized) formulation 50 2035-07-13
10849916 Cytoxan (Lyophilized) formulation 50 2035-07-13
11382923 Cytoxan (Lyophilized) formulation 50 2035-12-01
11382923 Cytoxan (Lyophilized) formulation 50 2035-12-01
11382923 Cytoxan (Lyophilized) formulation 50 2035-12-01

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10993952 Cytoxan (Lyophilized) formulation 42 2036-02-15
10993952 Cytoxan (Lyophilized) formulation 42 2036-02-15
9662342 Cytoxan (Lyophilized) formulation 42 2035-06-26
9662342 Cytoxan (Lyophilized) formulation 42 2035-06-26
10993952 Cytoxan (Lyophilized) formulation 50 2036-02-15
11382923 Cytoxan (Lyophilized) formulation 50 2035-12-01
11382923 Cytoxan (Lyophilized) formulation 50 2035-12-01
11382923 Cytoxan (Lyophilized) formulation 50 2035-12-01
10849916 Cytoxan (Lyophilized) formulation 50 2035-07-13
10849916 Cytoxan (Lyophilized) formulation 50 2035-07-13

Related